Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma

被引:0
作者
Tovoli, Francesco [1 ,2 ]
Pallotta, Dante Pio [1 ]
Vivaldi, Caterina [3 ]
Campani, Claudia [4 ]
Federico, Piera [5 ]
Palloni, Andrea [6 ]
Dalbeni, Andrea [7 ,8 ,9 ]
Solda, Caterina [10 ]
Lani, Lorenzo [1 ]
Svegliati-Baroni, Gianluca [11 ]
Garajova, Ingrid [12 ]
Ielasi, Luca [13 ]
De Lorenzo, Stefania [14 ]
Granito, Alessandro [1 ,2 ]
Stefanini, Bernardo [1 ]
Masi, Gianluca [3 ]
Marra, Fabio [4 ]
Lonardi, Sara [10 ]
Brandi, Giovanni [1 ]
Daniele, Bruno [5 ]
Auriemma, Alessandra [8 ,15 ]
Schiada, Laura [10 ]
Chen, Rusi [1 ]
Piscaglia, Fabio [1 ,2 ]
机构
[1] Univ Bologna, Dept Med & Surg Sci, Via Massarenti 9, I-40134 Bologna, BO, Italy
[2] IRCCS Azienda Osped Univ Bologna, Unit Internal Med Hepatobiliary & Immunoallerg Di, Bologna, Italy
[3] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[4] Univ Florence, Internal Med & Hepatol Unit, Dept Expt & Clin Med, Florence, Italy
[5] Osped Mare, Med Oncol Unit, Naples, Italy
[6] IRCCS Azienda Osped Univ Bologna, Oncol Unit, Bologna, Italy
[7] Univ Verona, Dept Med, Liver Unit, Verona, Italy
[8] Univ & Hosp Trust AOUI Verona, Verona, Italy
[9] Univ Verona & Hosp Trust AOUI Verona, Dept Med, Unit Gen Med C, Verona, Italy
[10] Veneto Inst Oncol IOV IRCCS, Oncol Unit 1, Padua, Italy
[11] Azienda Osped Univ Marche, Liver Injury & Transplant Unit, Ancona, Italy
[12] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[13] Osped Infermi Faenza, Dept Internal Med, Faenza, Italy
[14] Azienda USL Bologna, Oncol Unit, Bologna, Italy
[15] Univ Verona, Dept Engn Innovat Med DIMI, Sect Innovat Biomed, Oncol Area, Verona, Italy
关键词
Hepatocellular carcinoma; Sorafenib; Immunotherapy; Tyrosine kinase inhibitors; Outcome;
D O I
10.1016/j.dld.2024.07.035
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Most patients receiving atezolizumab-bevacizumab (AB) for hepatocellular carcinoma will eventually experience disease progression. Randomized clinical trials (RCTs) are undergoing to identify second-line treatments. Where RCTs are unavailable or patients are non-eligible, sorafenib is often prescribed based on approval and reimbursement policies. However, evidence supporting this approach is minimal. Objective: To assess the efficacy and safety of sorafenib in patients who permanently discontinued AB. Methods: The ARTE database prospectively collects patients treated with AB in a real-life setting. We analysed the outcome of patients who received sorafenib as second-line treatment. Results: Amongst 213 patients, 130 (61.0 %) permanently discontinued AB. Of them, 54 received second-line treatments, and sorafenib was prescribed in 40 patients. The disease control rate (DCR) was 10.0 %. The median progression-free (PFS) and overall survival were 3.3 (95 % confidence interval [CI] 2.7-3.9) and 6.9 months (95 % CI 2.7-11.1), respectively. Conclusions: In patients progressing under AB, the efficacy of sorafenib on different outcomes is limited. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页码:2079 / 2084
页数:6
相关论文
共 23 条
  • [1] Abou-Alfa Ghassan K, 2022, NEJM Evid, V1, pEVIDoa2100070, DOI 10.1056/EVIDoa2100070
  • [2] [Anonymous], Stivarga | European Medicines Agency
  • [3] [Anonymous], Lenvima | European Medicines Agency
  • [4] [Anonymous], Cabometyx | European Medicines Agency
  • [5] [Anonymous], Nexavar | European Medicines Agency
  • [6] Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab
    Campani, Claudia
    Vallot, Ariane
    Ghannouchi, Haroun
    Allaire, Manon
    Evain, Manon
    Sultanik, Philippe
    Sidali, Sabrina
    Blaise, Lorraine
    Thabut, Dominique
    Nahon, Pierre
    Seror, Olivier
    Ganne-Carrie, Nathalie
    Nault, Jean-Charles
    Wagner, Mathilde
    Sutter, Olivier
    [J]. HEPATOLOGY, 2024, 79 (01) : 49 - 60
  • [7] Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
    Chan, Stephen L.
    Ryoo, Baek-Yeol
    Mo, Frankie
    Chan, Landon L.
    Cheon, Jaekyung
    Li, Leung
    Wong, Kwan H.
    Yim, Nicole
    Kim, Hyeyeong
    Yoo, Changhoon
    [J]. JOURNAL OF HEPATOLOGY, 2024, 81 (02) : 258 - 264
  • [8] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Chen, Ching-Tso
    Feng, Yin-Hsun
    Yen, Chia-Jui
    Chen, San-Chi
    Lin, Yun-Tzu
    Lu, Li-Chun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Shao, Yu-Yun
    [J]. HEPATOLOGY INTERNATIONAL, 2022, 16 (05) : 1199 - 1207
  • [9] The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
    Ducreux, M.
    Abou-Alfa, G. K.
    Bekaii-Saab, T.
    Berlin, J.
    Cervantes, A.
    de Baere, T.
    Eng, C.
    Galle, P.
    Gill, S.
    Gruenberger, T.
    Haustermans, K.
    Lamarca, A.
    Laurent-Puig, P.
    Llovet, J. M.
    Lordick, F.
    Macarulla, T.
    Mukherji, D.
    Muro, K.
    Obermannova, R.
    O'Connor, J. -M.
    O'Reilly, E. M.
    Osterlund, P.
    Philip, P.
    Prager, G.
    Ruiz-Garcia, E.
    Sangro, B.
    Seufferlein, T.
    Tabernero, J.
    Verslype, C.
    Wasan, H.
    Van Cutsem, E.
    [J]. ESMO OPEN, 2023, 8 (03)
  • [10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247